Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis
Authors:
Open Access
- 19 July 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 22 (7) , e3002728
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive form of liver steatosis, the most common liver disease, and substantially increases the mortality rate. However, limited therapies are currently available to prevent MASH development. Identifying potential pharmacological treatments for the condition has been hampered by its heterogeneous and complex nature. Here, we identified a hepatic nonneuronal cholinergic signaling pathway required for metabolic adaptation to caloric overload. We found that cholinergic receptor nicotinic alpha 2 subunit (CHRNA2) is highly expressed in hepatocytes of mice and humans. Further, CHRNA2 is activated by a subpopulation of local acetylcholine-producing macrophages during MASH development. The activation of CHRNA2 coordinates defensive programs against a broad spectrum of MASH-related pathogenesis, including steatosis, inflammation, and fibrosis. Hepatocyte-specific loss of CHRNA2 signaling accelerates the disease onset in different MASH mouse models. Activation of this pathway via pharmacological inhibition of acetylcholine degradation protects against MASH development. Our study uncovers a hepatic nicotinic cholinergic receptor pathway that constitutes a cell-autonomous self-defense route against prolonged metabolic stress and holds therapeutic potential for combatting human MASH.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (R15AA031123)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107583)
- National Institute on Alcohol Abuse and Alcoholism (R01AA028761)
- National Institute on Aging (R01AG067753)
- National Science Foundation (DGE1841052)
- National Science Foundation (CHE1904146)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046960)
- National Institute of General Medical Sciences (P41GM108538)
- Michigan Life Sciences Fellowship
This publication has 81 references indexed in Scilit:
- Transcriptomic Cross‐Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and MiceHepatology Communications, 2021
- Non-alcoholic fatty liver disease in mice with hepatocyte-specific deletion of mitochondrial fission factorDiabetologia, 2021
- M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathwayBiochemical Pharmacology, 2019
- Cell culture models of fatty acid overload: Problems and solutionsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2018
- Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitisJournal of Gastroenterology, 2017
- Hypoxia and Hypoxia Inducible Factors: Diverse Roles in Liver DiseasesHepatology, 2011
- Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient miceBiochemical and Biophysical Research Communications, 2011
- Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I ExpressionDigestive Diseases and Sciences, 2010
- Vesicular acetylcholine transporter (VAChT) protein: A novel and unique marker for cholinergic neurons in the central and peripheral nervous systemsJournal of Comparative Neurology, 1997
- Intrahepatic distribution of nerves in the ratThe Anatomical Record, 1978